Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma

Clinical and Experimental Immunology

Volumn 106, Issue 1, 1996, Pages 73-78

  Yoshida, S ^a   Hashimoto, S ^a   Nakayama, T ^a   Kobayashi, T ^a   Koizumi, A ^a   Horie, T ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Bronchial asthma; IL 1 receptor antagonist; Soluble TNF receptor

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; HYDROCORTISONE SODIUM SUCCINATE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; ASTHMA; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0029737342     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-808.x     Document Type: Article

References (36)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225 44.
2. Djukanovie R, Roche W, Wilson JW et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142:434 57.
3. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992; 12:501 7.
4. Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87:893 910.
5. Shah A, Church MK, Holgate ST. Tumor necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995; 25: 1038 44.
6. Le J, Vilchek J. Tumor necrosis factor and interleukin-1 : cytokines with multiple overlapping biological activities. Lab Invest 1987;56:234-48.
7. Marini M, Avoni E, Hollemborg J et al. Cytokine mRNA profile and cell activation in bronchoalveolar lavage fluid from nonatopic patients with symptomatic asthma. Chest 1992; 102:661 9.
8. Broide DH, Lotz M, Cuomo AJ et al. Cytokine in symptomatic asthma airway. J Allergy Clin Immunol 1992; 89:958 67.
9. Krishaswamy G, Liu MC, Su SN et al. Analysis of cytokine transcript in the bronchoalveolar lavage cells of patients with asthma. Am J Respir Cell Mol Biol 1993; 9:279 86.
10. Ying S, Robinson DS, Varney V et al. TNF-α mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 24:745 50.
11. Gosset P, Tsicopoulos A, Wallaert B et al. Increased secretion of tumor necrosis factor α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991; 88:561 71.
12. Gosset P, Tsicopoulos A, Wallaert B et al. Tumor necrosis factor and interleukin-6 production by human mononuclear phagocytes from allergic asthmatics after IgE-dependent stimulation. Am Rev Respir Dis 1992; 146:768 74.
13. Borish L, Mascali JJ, Rosenwasser LJ. IgE-dependent cytokine production by human peripheral blood mononuclear phagocytes. J Immunol 1991; 146:63 66.
14. Kips JC, Tavernier J, Pauwels RA. Tumor necrosis factor causes bronchial hyperrresponsiveness in rats. Am Rev Respir Dis 1992; 145:332 6.
15. Herenandez A, Omini C, Daffonchio L. Interleukin-1: a possible mediator of lung inflammation and airway hyperreactivity. Pharmacol Res 1991; 24:385 93.
16. Wershil BK, Wang ZS, Grodon JR et al. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with administration with antiserum against tumor necrosis factor-alpha. J Clin Invest 1991; 87:446 53.
17. Watson ML, Smith D, Bourne AD et al. Cytokines contribute to airway dysfunction in antigen-challenged guinea pigs: inhibition of airway hyperreactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist. Am J Respir Cell Mol Biol 1993; 8:365 9.
18. Mullarkey MF, Leiferman KM, Peters MS et al. Human cutaneous allergic late phase response is inhibited by soluble IL-1 receptor. J Immunol 1994; 152:2033 41.
19. Arend WP, Interleukin-1 receptor antagonist. Adv Immunol 1993; 54:167 226.
20. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77:1627 52.
21. Shall TJ, Lewis M, Koller KJ et al. Molecular cloning and expression of a receptor for tumor necrosis factor. Cell 1990; 61:361 70.
22. Aderka D, Engelmann H, Maor Y et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175:323 9.
23. Seckinger P, Zang JH, Hauptmann B et al. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-reactivity with TNF receptor. Proc Natl Acad Sci USA 1990; 87:5188 92.
24. Girardin E, Roux-Lombard P, Grau GE et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunol 1992; 76:20 23.
25. Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of soluble tumor necrosis factor receptors in sarcoidosis. Clin Exp Immunol 1996; (accepted for publication).
26. Roux-Lombard P, Punzi L, Hasler F et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36:485 9.
27. Gabay C, Gay-Croisier F, Roux-Lombard P et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis dermatomyositis. Arthritis Rheum 1994; 37:1744 51.
28. Suzuki H, Takeyama H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythemutosus. Arthritis Rheum 1995; 38:1055 9.
29. Piguet RF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomysin or silica in mice. Eur Respir J 1994; 7:515 8.
30. Leff JA, Bodman ME, Cho OJ et al Post-insult treatment with interleukin-1 receptor antagonist decreases oxidative lung injury in rat given intratracheal interleukin-1. Am J Respir Crit Care Med 1994; 150:109 12.
31. Evans TJ. Moyes D, Carpenter A et al. Protective effect of 55- but not 75-kD tumor necrosis factor receptor-immunoglobulin G fusion proteins in animal model of Gram-negative sepsis. J Exp Med 1994; 180:2173 9.
32. Koizumi A, Hashimoto S, Kobayashi T et al. Elevation of serum soluble vascular cell adhesion molecule-1 (sVCAM-1) levels in bronchial asthma. Clin Exp Immunol 1995; 101:468 73.
33. Takishima T, Hida W, Sasaki H et al. Direct-writing recorder of the dose-response curve of the airway to methacoline. Chest 1981; 80:600 6.
34. Barnes PJ, Pederson S. Efficacy and safety of inhalated corticosteroids in asthma. Am Rev Respir Dis 1990; 142:1407 13.
35. Gehr G, Gentz R, Brockhaus M et al. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol 1992; 149:911 7.
36. Sim TC, Hilsmeiter KA, Reece LM et al. Interleukin-1 receptor antagonist protein inhibits the synthesis of IgE and proinflammatory cytokines by allergen-stimulated mononuclear cells. Am J Respir Cell Mol Biol 1994; 11:473 9.